SCHEMBL23906182

SCHEMBL23906182

COC(=O)c1nc(O)sc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.52
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 6/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 4/20 0.41
NPC1 O15118 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
KDM4C Q9H3R0 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
HPGD P15428 2/20 0.38
PKM P14618 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
RAF1 P04049 1/20 0.35
RNASEH1 O60930 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16417686 0.82 NPSR1 (0.54) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL1199384 0.80 NPSR1 (0.52) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL18974159 0.78 NPSR1 (0.50) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL794531 0.78 ALDH1A1 (0.55) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL2142507 0.76 NPSR1 (0.47) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL4852589 0.76 NPSR1 (0.47) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL14820304 0.72 NPSR1 (0.42) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL19565681 0.71 NPSR1 (0.41) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL7138779 0.71 RAB9A (0.49) NPSR1KDM4EALDH1A1KMT2AMAPT
SCHEMBL8951086 0.70 NPSR1 (1.00) NPSR1KDM4EALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed
CN-102459232-B 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof SANOFI AVENTIS 2014-05-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 NPSR1 3773/4885KDM4E 4443/4885ALDH1A1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.